Skip to content
Peptide research

Gonadorelin

Also known as Factrel · Lutrepulse · GnRH
Category
Hormone & Sexual Health
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic form of GnRH, well studied for triggering LH and FSH release to induce ovulation and test pituitary function. Its trendy longevity-clinic use, preserving testicular function during TRT, is speculative and unproven in humans. The key risk is dosing: continuous, non-pulsatile use paradoxically shuts down the axis it's meant to stimulate, and rare anaphylaxis is reported. Not FDA-approved for that use; supply is compounded or research-grade.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Stimulates endogenous LH and FSH production

    High

    Reproducible, dose-dependent LH and FSH rise in humans, basis of an FDA-approved diagnostic test.

  • Induces ovulation in hypothalamic amenorrhea

    High

    Approved therapy; pulsatile dosing produced ovulation in about 94-96% of women in clinical trials.

  • Stimulates spermatogenesis in hypogonadotropic hypogonadism

    Medium

    Pulsatile GnRH pump therapy induced sperm production in about 61% of men in a 2024 study.

Evidence limits

Evidence Level
Level 1-2 — Strong

Gonadorelin has decades of Level I-II evidence for ovulation induction in hypothalamic amenorrhea and spermatogenesis induction in hypogonadotropic hypogonadism. The diagnostic GnRH stimulation test is a well-validated clinical tool. Its use as an HCG alternative in TRT protocols is supported by mechanistic rationale and clinical experience but lacks large randomized controlled trials.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Hormone-sensitive cancers (prostate, breast)

    High

    Initial LH/FSH surge can temporarily increase sex hormone levels before suppression.

General cautions

  • Pregnancy

    Absolute

    Can disrupt pregnancy hormones.

Risk summary(13)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Headache, nausea, lightheadedness, and abdominal discomfort (uncommon)

    Low
  • Injection site reactions including pain, swelling, induration, and pruritus

    Low
  • Hypersensitivity/anaphylactic reactions (rare but reported; caution on re-administration)

    Moderate
  • Flushing and tachycardia (rare)

    Low
  • Bronchospasm (rare)

    Low
  • Multiple pregnancy risk when used for ovulation induction (12% incidence in clinical trials)

    High
  • Ovarian hyperstimulation syndrome (rare, especially with concurrent clomiphene)

    Low
  • Antibody formation with repeated administration (rare)

    Low
  • Risk of pituitary apoplexy if administered to patients with undiagnosed pituitary adenoma

    Low
  • Menorrhagia (frequency unknown)

    Theoretical
  • Paradoxical pituitary downregulation with continuous (non-pulsatile) high-dose administration

    High
  • Potential worsening of hormone-dependent tumors due to initial gonadotropin surge

    Theoretical
  • Skin allergic reactions at pump infusion site (noted in pulsatile pump studies)

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.